Approval · Notice of Compliance 25548 · 2021
CABENUVA: Notice of Compliance 25548
Issued March 26, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25548
- Date
- March 26, 2021
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosing regimen
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CABENUVA | Not yet assigned | — |
| VOCABRIA | Not yet assigned | — |
Medicinal ingredients
- CABOTEGRAVIR 400 MG per 2ML
- RILPIVIRINE 600 MG per 3ML
- CABOTEGRAVIR 600 MG per DOSE
- RILPIVIRINE 300 MG per ML
- CABOTEGRAVIR 30 MG per TAB